MARKET NEWS

Hyloris Successfully Renegotiates License Agreements for Lead Products With the Alter Pharma Group
VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host Disease
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts With Menin Inhibitor KO-539
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
CHMP Recommends Approval of RINVOQ (upadacitinib) for the Treatment of Atopic Dermatitis
Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination With Cabozantinib in Clear Cell Renal Carcinoma

  FEATURED EDITORIAL

  COMPANY PROFILE

PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialization, delivering speed-to-market and commercial success for our customers. Our core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply. We partner with clients in providing innovative technologies, flexible solutions, and an integrated supply network supporting lifesaving medicines destined to over 100 countries around the world. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Toward Industrialization of Induced Pluripotent Stem Cell-Based Therapies

Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Toward Industrialization of Induced Pluripotent Stem Cell-Based Therapies

Catalent recently announced it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs)…..

Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients With X-ALD

Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients With X-ALD

Viking Therapeutics, Inc. recently announced the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRb), in patients with X-linked….

Fulcrum Therapeutics Announces Results from ReDUX4 Trial With Losmapimod in Facioscapulohumeral Muscular Dystrophy Demonstrating Slowed Disease Progression & Improved Function

Fulcrum Therapeutics Announces Results from ReDUX4 Trial With Losmapimod in Facioscapulohumeral Muscular Dystrophy Demonstrating Slowed Disease Progression & Improved Function

Fulcrum Therapeutics, Inc. recently announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy (FSHD). Results being presented with….

Prothena Announces Bristol Myers Squibb Opt-In of Anti-Tau PRX005 as the First Program From Global Neuroscience Research & Development Collaboration

Prothena Announces Bristol Myers Squibb Opt-In of Anti-Tau PRX005 as the First Program From Global Neuroscience Research & Development Collaboration

Prothena Corporation plc recently announced Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive US license for….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 14 – Parenteral Contract Manufacturing
July 21 – Bioavailability